Dutch oncology clinical services SME with H2020 experience in glioma trials and biodegradable nanomedicine scale-up for cancer immunotherapy.
Specialized Medical Services-Oncology BV is a Dutch SME that provides clinical and medical operations support for oncology research, particularly in the context of sponsored clinical trials. Their participation in both a Phase IIB clinical trial (CLINGLIO) and a nanomedicine scale-up project (PRECIOUS) points to a contract research or clinical services profile — the kind of company that helps move cancer treatments from the lab into patients. Based in Schiphol, a hub for international medical logistics and CRO activity, they are positioned to support multinational oncology trials across Europe. Their dual involvement in immuno-oncology and glioma trials suggests they serve as a specialist clinical partner rather than a drug developer.
Both PRECIOUS and CLINGLIO are cancer-focused projects — one a Phase IIB clinical trial in glioma, the other a translational nanomedicine scale-up — indicating consistent clinical oncology involvement.
CLINGLIO involved a Phase IIB trial with the lipid 2OHOA in newly-diagnosed malignant glioma patients, a highly specialized and rare indication requiring dedicated clinical expertise.
PRECIOUS focused on scaling up biodegradable nanomedicines for multimodal precision cancer immunotherapy, indicating familiarity with next-generation oncology delivery systems.
With only two projects starting in 2016 and 2017 — both running through 2022 — there is no meaningful chronological evolution to trace; the organization entered H2020 with a consistent oncology focus and did not visibly shift between early and late participation. What can be observed is a dual-track positioning: one project rooted in translational nanomedicine (earlier, more research-stage) and one in late-phase clinical trials (a more execution-oriented role). This suggests the organization may have broadened its service scope from research support toward active clinical trial management over time, but the data is too thin to confirm a directional trend.
Their trajectory points toward active involvement in late-phase oncology clinical trials, making them a relevant partner for consortia needing clinical execution capacity in rare or hard-to-treat cancers.
They have never coordinated an H2020 project — both roles were as consortium participant, suggesting they prefer or are positioned as specialist contributors rather than project leads. Despite only two projects, they engaged with 23 unique partners across 12 countries, indicating they join large, multinational consortia where they fill a defined clinical or medical services niche. This pattern is typical of CROs and clinical service providers that add value through access to patients, trial infrastructure, or regulatory expertise rather than through intellectual property or research leadership.
With 23 unique consortium partners across 12 countries from just two projects, this is a well-networked SME relative to its H2020 size — each project plugged it into large, geographically diverse consortia. No geographic concentration is visible; the Schiphol base suggests international reach is operationally normal for them.
This is one of the few private oncology clinical services SMEs in the Netherlands with direct H2020 track record in both nanomedicine translation and late-phase clinical trials — a rare combination that spans the research-to-clinic pipeline. For a consortium building around a cancer therapy candidate that needs both scientific credibility and clinical execution, this organization offers a bridge between those two worlds. Their SME status also makes them eligible for roles that improve a consortium's SME participation rate, which is often a scoring factor in Horizon proposals.
